



Breast Cancer Brain Metastasis and Leptomeningeal Disease

Guest Editors:

Dr. Albert Grinshpun

Dr. Sarah Sammons

Dr. Nancy U. Lin

Deadline for manuscript
submissions:

15 September 2024

Message from the Guest Editors

Brain metastases are the most common intracranial malignancy. About one in five patients with metastatic breast cancer will develop brain metastases (BMs) during their disease course. Specifically, HER2-positive and triple-negative breast cancer subtypes have higher incidences of BMs, with recent data suggesting an increase in the overall incidence of MBC-related BMs in Western countries. Historically, BMs were associated with poor prognoses; however, novel approaches and therapies are starting to change the paradigm in patients with MBC-related BMs. Furthermore, BMs from metastatic breast cancer were found to have unique clinical and molecular features when compared to other tumor types, highlighting the need for further specific investment and research in this field.

Our goal in the current Special Issue of *Cancers* is to shed light on the latest advancements in this perplexing field and raise awareness of the most significant contemporary challenges in the diagnosis, monitoring, treatment, and prognostication of patients with metastatic breast cancer and BMs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)